Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Dr. Reddy's Laboratories Ltd. (NYSE: RDY).

Full DD Report for RDY

You must become a subscriber to view this report.


Recent News from (NYSE: RDY)

Nostrum Labs hikes price of mature antibiotic 400%
In a move that would make Martin Shkreli proud, privately held Nostrum Laboratories has increased the price of antibiotic nitrofurantoin, on the market since 1953 to treat bladder infections, 400%. A bottle of the pills now costs $2,393, up from ~$475. More news on: Amneal Pharmaceutical...
Source: SeekingAlpha
Date: September, 12 2018 11:50
Dr. Reddy's Laboratories launches Neostigmine Methylsulfate Injection, USP in U.S.
Dr. Reddy’s Laboratories (NYSE: RDY ) announces the launch of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Avadel Legacy Pharmaceuticals' Bloxiverz (Neostigmine Methylsulfate) Injection approved by the FDA. More news on: Dr. Reddy's La...
Source: SeekingAlpha
Date: September, 12 2018 09:13
Dr. Reddy's Laboratories Announces the Launch of Neostigmine Methylsulfate Injection, USP in the U.S. Market
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz (N...
Source: Business Wire
Date: September, 12 2018 08:31
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Ltd. - RDY
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529...
Source: ACCESSWIRE IA
Date: August, 08 2018 21:15
FDA OKs first generic drug under new accelerated pathway
The FDA has approved Apotex's potassium chloride oral solution for the treatment and prevention of hypokalemia (low blood potassium) in patients on diuretics and when dietary management with potassium-rich foods is inadequate or diuretic dose reduction is not possible. More news on: Myla...
Source: SeekingAlpha
Date: August, 08 2018 11:38

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1435.6335.5835.6335.42112,290
2017-09-0134.6334.6735.9334.001,009,853
2017-08-3131.6832.1932.2131.18565,576
2017-08-3031.7031.5431.7031.35125,631
2017-08-2931.6031.7331.7931.38273,128

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-131,1171,62868.6118Short
2018-12-122,0343,20463.4831Short
2018-12-1111,03113,22083.4418Short
2018-12-107032,40329.2551Cover
2018-12-072,2873,14172.8112Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RDY.


About Dr. Reddy's Laboratories Ltd. (NYSE: RDY)

Logo for Dr. Reddy's Laboratories Ltd. (NYSE: RDY)

Not available

 

Contact Information

 

 

Current Management

  • Santosh K. Nair / Secretary

Current Share Structure

  • Market Cap: $4,798,222,591 - 05/29/2018
  • Issue and Outstanding: 165,741,713 - 03/31/2017

 


Recent Filings from (NYSE: RDY)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: September, 13 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: September, 12 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: September, 05 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 23 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 06 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 30 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 26 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 26 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 20 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 16 2018

 

 


Daily Technical Chart for (NYSE: RDY)

Daily Technical Chart for (NYSE: RDY)


Stay tuned for daily updates and more on (NYSE: RDY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: RDY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RDY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RDY and does not buy, sell, or trade any shares of RDY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/